APA (7th ed.) Citation

Finazzi, T., Holer, L., Tang, H., Riesterer, O., Allal, A., Elicin, O., . . . Scheibe, B. (2024). 484: SAKK 16/18: QA and interim safety of immune-modulatory RT in resectable stage III(N2) NSCLC. Radiotherapy & Oncology, 194, S1610. https://doi.org/10.1016/S0167-8140(24)01092-2

Chicago Style (17th ed.) Citation

Finazzi, Tobias, et al. "484: SAKK 16/18: QA and Interim Safety of Immune-modulatory RT in Resectable Stage III(N2) NSCLC." Radiotherapy & Oncology 194 (2024): S1610. https://doi.org/10.1016/S0167-8140(24)01092-2.

MLA (9th ed.) Citation

Finazzi, Tobias, et al. "484: SAKK 16/18: QA and Interim Safety of Immune-modulatory RT in Resectable Stage III(N2) NSCLC." Radiotherapy & Oncology, vol. 194, 2024, p. S1610, https://doi.org/10.1016/S0167-8140(24)01092-2.